The Quantellect read.As of Nov 19, 2026, 10 active firms cover Goodrx Holdings Inc: 3 rate it Buy or better, 6 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets range widely, $2.50 to $5.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $3.89 sits 16% above the current $3.36. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.08 next quarter toward $0.35 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Neutral
Strong Buy00%
Buy330%
Neutral660%
Sell110%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$3.89
+15.7% upside
Average target across 9 active firms as of Nov 19, 2026 vs $3.36 current
Highest Target$5.00
Average Target$3.89
Lowest Target$2.50
Detailed analyst forecasts for GDRX
Showing 1–9 of 9 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 3 of 10 active firms rate GDRX a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GDRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.08
Range $0.07 – $0.10 · 11 analysts · -12% YoY
Next period, 11 analysts expect Goodrx Holdings Inc to earn $0.08 a share (range $0.07 – $0.10), versus $0.09 a year earlier. Full-year consensus is $0.30, growing to $0.35 the year after.
REVENUE · NEXT QUARTER
$202.1M
Range $196.7M – $205.1M · 11 analysts · +4% YoY
Revenue is expected to reach $202.1M (range $196.7M – $205.1M), +3.8% year-over-year. Full-year consensus is $798.5M, rising to $836.2M next year.
Top analysts covering Goodrx Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GDRX.
#1
Kevin Caliendo
UBS · Rank #165
Neutral
$3.75+11.6% to target
Overall win rate
42%
+ Follow
#2
Brian Tanquilut
Jefferies · Rank #280
Neutral
$2.75-18.2% to target
Overall win rate
46%
+ Follow
#3
Scott Schoenhaus
Keybanc · Rank #540
Buy
$6.00+78.6% to target
Overall win rate
30%
+ Follow
#4
Eric Sheridan
Goldman Sachs · Rank #545
Neutral
$4.00+19.0% to target
Overall win rate
31%
+ Follow
#5
Daniel Grosslight
Citigroup
Buy
$5.00+48.8% to target
Coverage
—
+ Follow
GDRX stock forecast FAQ
What is GDRX's average 12-month price target?+
The 9 active firms with a live target average $3.89 for Goodrx Holdings Inc over the next 12 months, ranging from a $5.00 high to a $2.50 low, as of Nov 19, 2026.
Is GDRX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 10 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 6 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GDRX?+
The Street-high target is $5.00 (Citigroup), and the Street-low is $2.50 (Goldman Sachs). The average of all 9 active-firm targets is $3.89.
How many active Wall Street firms cover GDRX?+
10 active firms have a recognized rating on Goodrx Holdings Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GDRX?+
Among analysts who currently cover GDRX, Kevin Caliendo of UBS has the strongest overall Quantellect track record (Rank #165). Their current call is Neutral with a $3.75 target.
What is Goodrx Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $0.08 per share (range $0.07 – $0.10) across 11 analysts. Full-year EPS is projected at $0.30, rising to $0.35 the following year.
How much revenue is Goodrx Holdings Inc expected to report next quarter?+
Consensus revenue is $202.1M (range $196.7M – $205.1M). Full-year revenue is projected at $798.5M, growing to $836.2M next year.
Have analysts been upgrading or downgrading GDRX lately?+
As of Nov 19, 2026, 3 of 10 active firms rate GDRX a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GDRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.